Latest Health News
EU Political Agreement on New Pharmaceutical Legislation
The EMA welcomed a political agreement reforming EU pharmaceutical legislation to modernize medicine development, authorization, and access while enhancing supply security and innovation. This major update aims to improve patient outcomes across Europe.
A related podcast episode focuses on pandemic preparedness.
CHMP Positive Opinion for Uplizna in Generalized Myasthenia Gravis
The EMA's CHMP adopted a positive opinion for Uplizna (inebilizumab) as an add-on therapy for adult gMG patients who are anti-AChR or anti-MuSK antibody positive. This expands treatment options for this neurological condition.
Approval could follow soon pending European Commission decision.
EMA Recommends Refusal of Blarcamesine for Alzheimer’s Disease
The European Medicines Agency recommended refusing marketing authorization for blarcamesine (Anavex) intended for Alzheimer’s treatment after a negative CHMP opinion. This decision highlights ongoing challenges in Alzheimer’s drug approvals.
Further data may be required for reconsideration.
New Data on Antimicrobial Sales in Animals
EMA published its second annual report showing a slight increase in antimicrobial sales for animals and launched a public dashboard for veterinary data. This surveillance aids in combating antimicrobial resistance.
The tool enhances transparency for stakeholders.
UN Landmark Declaration Integrates NCDs and Mental Health
World leaders adopted a UN declaration addressing noncommunicable diseases and mental health together, setting 2030 targets for tobacco reduction, hypertension control, and mental health access. It emphasizes interconnected physical-mental health and system strengthening.
Progress will be reviewed at future high-level meetings.
Gene-Edited Pig Liver Functions 10 Days in Human
Chinese researchers reported a six-gene-edited pig liver functioning in a human for 10 days without rejection, advancing xenotransplantation as a bridge to human donors. The procedure monitored bile production successfully.
Long-term replacement remains a future goal.
AMT-130 Gene Therapy Slows Huntington’s Disease Progression
UniQure’s Phase 1/2 trial of AMT-130 showed slowed HD progression, safety, and dose-dependent HTT protein reduction. This transformative news boosted HD community hopes.
Further trials are anticipated.
VIZZ Eye Drops Correct Presbyopia for 10 Hours
LENZ Therapeutics’ VIZZ eye drops provide up to 10 hours of vision correction for age-related farsightedness affecting billions worldwide. This non-invasive alternative to reading glasses won a health innovation award.
It targets a guaranteed aging condition.
Carvykti Achieves Long-Term Remission in Multiple Myeloma
Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvykti yielded long-term survival in incurable multiple myeloma, with potential for earlier use. It retrains patient white blood cells to fight cancer.
FDA-approved since 2022, 2025 data stirred excitement.
FDA Breakthrough Designation for STK-001 in Dravet Syndrome
STK-001 received FDA breakthrough therapy designation for Dravet syndrome, aiming to restore NaV1.1 protein and reduce seizures. This antisense oligonucleotide shows promise for epilepsy treatment.
December 2025 update highlights neurology progress.
Nine Conflict Zones Face Hospital IT Collapse
Black Book identified nine conflict-driven 'hospital IT collapse zones' including Gaza, Afghanistan, and Ukraine, urging EMR vendors for a 2026 connectivity compact. Restoration focuses on interoperability and workforce rebuilding.
Connectivity is deemed essential for patient safety.
Axolotl Regeneration Research Advances Human Limb Repair
Scientists decoded axolotl limb regeneration via retinoic acid signaling, drawing parallels to human healing and offering insights to shift from scarring to regeneration. Gene work with shox links to human biology.
This conceptual breakthrough fuels regenerative medicine.